Together We Offer More

In an effort to expand clinical trial testing to Asia, Pacific Biomarkers partnered with Syngene International Ltd. and Wuxi AppTech in 2011 and 2014, respectively.

Syngene International Ltd., a Biocon company, is a leading custom research and manufacturing organization supporting drug development from lead generation to clinical supplies. Syngene offers bioanalytical services (for small molecules and biologics) in addition to specialty tests such as immunogenicity screening assays, neutralizing antibody assays, cell based assays and ligand binding characterization assays. Clinical laboratory services provided by Syngene range from moderate to high complexity assays such as customized flow cytometry and immunohistochemistry assays. The Pacific Biomarkers-Syngene partnership combines biomarker support for clinical trial research of the former with development capabilities of ligand binding assays of the latter in a cost-effective business model situated in India. Both laboratories are CAP and GLP certified with strong emphasis on regulatory compliance and quality assurance providing reliable analytical data that stands up to the most rigorous regulatory and scientific scrutiny.

WuXi AppTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The Pacific Biomarkers-WuXi partnership allows us to support a broader spectrum of companies developing medicines in Asia with special emphasis on clinical trials performed in China.

Through our strategic collaborations, Pacific Biomarkers can offer its 300+ CLIA validated biomarkers across diverse therapeutic areas in Asia with added capabilities within immunogenicity and cell based functional assays in a cost-effective business model.